aTyr Pharma, Inc. (ATYR)
| Market Cap | 81.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -66.64M |
| Shares Out | 97.99M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,629,207 |
| Open | 0.8200 |
| Previous Close | 0.8246 |
| Day's Range | 0.7995 - 0.8469 |
| 52-Week Range | 0.6816 - 7.2900 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 8.88 (+961.82%) |
| Earnings Date | Nov 6, 2025 |
About ATYR
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease rela... [Read more]
Financial Performance
In 2024, aTyr Pharma's revenue was $235,000, a decrease of -33.43% compared to the previous year's $353,000. Losses were -$64.02 million, 27.1% more than in 2023.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ATYR stock is "Buy." The 12-month stock price target is $8.88, which is an increase of 961.82% from the latest price.
News
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens Berman
SAN FRANCISCO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its ...
Ethos Technologies Targets IPO Amid Positive Insurance Offerings
Ethos Technologies Inc. has filed for a $100 million IPO and provides a three-sided digital life insurance marketplace platform. LIFE is growing rapidly and profitably, with strong revenue, gross marg...
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its...
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society Congress 2025
Ethos Files Registration Statement for Proposed Initial Public Offering
AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it filed a registration ...
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman
SAN FRANCISCO , Sept. 23, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its la...
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
SAN FRANCISCO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its...
Top 3 Health Care Stocks That May Explode In September
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
LOS ANGELES , Sept. 18, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR) for viola...
Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma's Phase 3 Clinical Trial Results
CHICAGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) expresses both solidarity and resolve as aTyr Pharma announced that its Phase 3 trial of efzofitimod in pulmon...
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FITÔ Study Failure Drives Shares 80% Lower -- Hagens Berman
SAN FRANCISCO , Sept. 17, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its la...
ATyr Pharma, Inc. (ATYR) Announces Top Line Results For The Phase III EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis (Transcript)
aTyr Pharma, Inc. (NASDAQ:ATYR) Announces Top Line Results for the Phase III EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis September 15 2025 11:00 AM EDT Company Participants Ashlee Dunston ...
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
LOS ANGELES--(BUSINESS WIRE)---- $ATYR--aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR.
ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results
Biotech firm aTyr Pharma Inc. ATYR plummeted over 81% at last check on Monday, with a session volume of 34.7 million compared to the average volume of 4.83 million as per data from Benzinga Pro.
BREAKING: aTyr Pharma Shares Plummet 80%; Investors Should Contact Block & Leviton to Potentially Recover Losses
BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating aTyr Pharma, Inc. (Nasdaq: ATYR) for potential securities law violations.
aTyr Pharma's lung disease drug misses main goal in late-stage trial
aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, a disease imp...
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...
Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors
AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. ...
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally ...
aTyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its propr...
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. ...